Researchers have developed an artificial pancreas system that can measure diabetes in patients. This artificial system uses a smartphone app which works with a glucose sensor and insulin pump to control diabetes.
This research was published in a journal, Mary Ann Liebert, Inc on 8 January 2019.
An artificial pancreas system has passed a preliminary trial that was done on people with type 1 diabetes. The new app was tested as per the protocols of Food and Drug Administration (FDA).
The type 1 diabetes patients have to check their blood sugar levels all over the day. A few patients use insulin pumps. The insulin pumps deliver a predefined level of the hormone to the body which works for 24 hours a day.
The insulin pumps might fail due to uneven meal consumption or exercise. These activities throughout the day can increase the blood sugar levels or it might drop. It requires the patients to set the levels of insulin in their body.
The senior author of the study, Eyal Dassau said, “People can manage their diabetes without needing to pull out an insulin pump or sensor in public. You can just look at a screen and no one will know you have diabetes.”
Dassau added, “Today’s pumps can keep a steady flow of insulin that can be modulated by the user with a turn off the button if glucose levels fluctuate. But these are not “smart” devices.”
Dr. NG added, “So, what happens when you’ve lost the ability to modulate insulin is you lose the ability to direct sugar where to go or when to stay in the blood. And because of that, you have to be given insulin.”
The artificial pancreas systems are the devices that are developed meticulously. These devices make a replica of the glucose-regulating function of the fit pancreas. These devices monitor the levels of glucose in the body. Also, the device automatically regulates the circulation of insulin in the body.
This helps to reduce the levels of high blood sugar and controls the low blood glucose. The Food and Drug Administration explains artificial pancreas system can help in better control of blood sugar levels in type 1 diabetes patients.
The artificial pancreas was used for 48-hours after one week of sensor-augmented pump (SAP) on the participants. The system of artificial pancreas (AP) was challenged by the participants who performed extensive walking without giving alerts to the controller.
They consumed large meals at the restaurants continuously for two nights. They even ate ice creams. After these intentional challenges, the comparison of the SAP with the AP study gave an improved trend.
The iAPS system gave reliable results and presented healthy connectivity with the peripheral devices. The device doesn’t require frequent user interventions.
The six patients didn’t experience the high blood sugar throughout the process. They even had the high carb meals but the blood sugar level was found low.
The best thing about this artificial app is that it can wirelessly interface with the glucose monitors, decision-making algorithms or insulin pumps in an unlocked smartphone.
But the problem with this new study is that it took lesser time and we cannot draw effective conclusions based on the research.